The aim of this non-interventional study is to ensure that patients in routine clinical
practice follow given treatment instructions and to evaluate the number of reliever
inhalations as well as the number of patient/days with more than 8/12 total inhalations at
any day. If the number of reliever inhalations and thus the received inhaled
glucocorticosteroid dose is not excessive, the safety conclusions from the clinical studies
can be extrapolated to real life for better acceptance of SMART (Symbicort Maintenance and
Reliever Therapy).
Latvia Information Clinical Study, Information, Phone: +371 67377100, Email: agrita.hartmane@astrazeneca.com
Research Site, Aozkraukle, Latvia; Recruiting
Research Site, Aluksne, Latvia; Recruiting
Research Site, Balvi, Latvia; Recruiting
Research Site, Cesis, Latvia; Recruiting
Research Site, Gulbene, Latvia; Recruiting
Research Site, Jekabpils, Latvia; Recruiting
Research Site, Jumprava, Latvia; Recruiting
Research Site, Kekava, Latvia; Recruiting
Research Site, Kraslava, Latvia; Recruiting
Research Site, Kuldiga, Latvia; Recruiting
Research Site, Limbazi, Latvia; Recruiting
Research Site, Liepaja, Latvia; Recruiting
Research Site, Livani, Latvia; Recruiting
Research Site, Madona, Latvia; Recruiting
Research Site, Ogre, Latvia; Recruiting
Research Site, Preili, Latvia; Recruiting
Research Site, Rezekne, Latvia; Recruiting
Research Site, Salacgriva, Latvia; Recruiting
Research Site, Saldus, Latvia; Recruiting
Research Site, Talsi, Latvia; Recruiting
Research Site, Valniera, Latvia; Recruiting
Research Site, Ventspils, Latvia; Recruiting
